| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Net revenue | ||||||||
7,530 | 6,057 | 7,205 | 5,666 | 4,676 | 3,544 | 4,039 | 2,915 | 2,519 |
Cost of revenue | ||||||||
2,670 | 2,316 | 2,989 | 2,333 | 2,103 | 2,045 | 1,907 | 1,736 | 1,595 |
Gross profit | ||||||||
4,860 | 3,741 | 4,216 | 3,333 | 2,573 | 1,499 | 2,132 | 1,179 | 924 |
Operating expenses: | ||||||||
Research, development and clinical trials | ||||||||
6,225 | 6,262 | 4,939 | 4,787 | 3,882 | 3,486 | 3,272 | 3,433 | 3,465 |
Selling, general and administrative | ||||||||
6,652 | 6,173 | 6,519 | 6,251 | 4,653 | 4,374 | 2,799 | 2,902 | 2,240 |
Total operating expenses | ||||||||
12,877 | 12,435 | 11,458 | 11,038 | 8,535 | 7,860 | 6,071 | 6,335 | 5,705 |
Loss from operations | ||||||||
-8,017 | -8,694 | -7,242 | -7,705 | -5,962 | -6,361 | -3,939 | -5,156 | -4,781 |
Other income (expense): | ||||||||
Interest expense | ||||||||
1,042 | 1,063 | 1,084 | 1,113 | 1,093 | 1,073 | 1,076 | 313 | 258 |
Change in fair value of preferred stock warrant liability | ||||||||
0 | 0 | 0 | 614 | -273 | 122 | 183 | 210 | 30 |
Other income (expense), net | ||||||||
217 | 590 | 56 | 247 | -103 | -61 | 101 | -428 | 175 |
Total other expense, net | ||||||||
-825 | -473 | -1,028 | -1,480 | -923 | -1,256 | -1,158 | -951 | -113 |
Loss before income taxes | ||||||||
-8,842 | -9,167 | -8,270 | -9,185 | -6,885 | -7,617 | -5,097 | -6,107 | -4,894 |
Provision for income taxes | ||||||||
10 | 10 | 10 | 10 | 10 | 18 | 8 | 8 | 7 |
Net loss | ||||||||
-8,852 | -9,177 | -8,280 | -9,195 | -6,895 | -7,635 | -5,105 | -6,115 | -4,901 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||||
-0.42 | 3.59 | -0.39 | -0.70 | -4.86 | -8.84 | -3.73 | -1.30 | -3.61 |
Weighted average common shares outstanding, basic and diluted | ||||||||
21,221 | 21,135 | 21,131 | 13,133 | 1,418 | -1,978 | 1,368 | 4,686 | 1,358 |